Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Hagop Kantarjian(The University of Texas MD Anderson Cancer Center), Brian Druker(Oregon Health & Science University)
Cited by 2,028
Related Papers
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
|Blood|2010|399
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
|Cancer Cell|2014|366
An expanded universe of cancer targets
|Cell|2021|221